Mar, 2010

U.S.A.
News / Corporate
Astellas Responds to OSI Pharmaceuticals' Rejection
Astellas Pharma Inc. (TSE: 4503) today released the following statement in response to OSI Pharmaceuticals' (NASDAQ: OSIP) rejection of Astellas' tender offer for $52.00 per share. Astellas is...
Read More
U.S.A.
News / Corporate
Astellas Pharma Inc. Commences Tender Offer to Acquire All Outstanding Shares of OSI Pharmaceuticals for $52 per Share in Cash
Astellas Pharma Inc. (TSE: 4503), a global pharmaceutical company, today announced that its indirect subsidiary, Ruby Acquisition, Inc., has commenced a cash tender offer for all outstanding...
Read More
U.S.A.
News / Corporate
Astellas Pharma Inc. Offers to Acquire OSI Pharmaceuticals for $52.00 Per Share in Cash
Astellas Pharma Inc. (TSE: 4503), a global pharmaceutical company, will commence a tender offer to acquire all outstanding shares of common stock of OSI Pharmaceuticals (NASDAQ: OSIP) for $52.00...
Read More

Jan, 2010

U.S.A.
News / Corporate
OSI Pharmaceuticals, Inc. Announces Fourth Quarter and 2009 Full Year Tarceva Sales at JP Morgan Healthcare Conference
MELVILLE, N.Y., Jan 12, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) will present fourth quarter and year end Tarceva(R) (erlotinib) sales today during the Company's...
Read More

Dec, 2009

U.S.A.
News / Corporate
U.S. Patent and Trademark Office Grants Reissued Patent Replacing OSI Pharmaceuticals' Tarceva(R) Composition of Matter Patent
MELVILLE, N.Y., Dec 29, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced that the U.S. Patent & Trademark Office (PTO) has granted reissue patent RE41,065,...
Read More